Vanguard Group
CTNM

Vanguard Group’s Contineum Therapeutics CTNM Stock Holding History

Vanguard Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$14.5M Buy
1,270,858
+306,626
+32% +$3.5M ﹤0.01% 2770
2025
Q3 		$11.3M Buy
964,232
+220,231
+30% +$1.78M ﹤0.01% 2914
2025
Q2 		$2.95M Sell
744,001
-59,427
-7% -$258K ﹤0.01% 3389
2025
Q1 		$5.61M Sell
803,428
-5,655
-0.7% -$51.4K ﹤0.01% 3123
2024
Q4 		$11.9M Buy
809,083
+347,756
+75% +$5.51M ﹤0.01% 2861
2024
Q3 		$8.83M Sell
461,327
-10,290
-2% -$197K ﹤0.01% 3019
2024
Q2 		$8.31M Buy
+471,617
New +$7.6M ﹤0.01% 3025

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group's CTNM Position: Q4 2025 in Review

Vanguard Group increased its Contineum Therapeutics (CTNM) stake by 32% in Q4 2025, buying an estimated $3.5M and bringing the position to 1,270,858 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2770.

Vanguard Group first reported a position in CTNM in Q2 2024 and has held it in 7 quarters since. 80 funds tracked by Wall St. Rank hold CTNM as of Q4 2025.

  • Vanguard Group held 1,270,858 shares of Contineum Therapeutics worth $14.5M as of Q4 2025.
  • Vanguard Group bought 306,626 Contineum Therapeutics shares in Q4 2025, an estimated $3.5M.
  • Contineum Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2770 holding.
  • Vanguard Group first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 80 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.